"We are excited to be working with Caliper Life Sciences, one of the leading companies in developing innovative tools that enable next generation drug development," said Jeffrey Otto, National Director of the Center for Translational Research. "Partnerships such as this one are essential to our mission at the CTR to help advance personalized medicine."
"We are pleased to have entered into this new collaboration with the Center for Translational Research," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "With increasing incidence of oncology drug candidates failing in late-stage clinical trials, and with rapidly expanding knowledge of clinically relevant biomarkers, it is critical to develop comprehensive and disease-relevant cancer models that can be used to guide patient stratification to improve clinical safety and efficacy. Access to human tumor samples through our new collaboration with CHI will complement Caliper's broad offering of translational research services and contribute to our programs to reduce attrition or rescue failed drug candidates. Taken together, our personalized medicine strategies should facilitate the development of therapeutics and companion diagnostics to ultimately improve treatment success rates."
More information on this research collaboration can be obtained from Caliper (booth #332) at the 102nd American Association for Cancer Research (AACR) Annual Meeting, April 2-6, 2011 in Orlando, Florida.
About the Center for Translational Research (CTR)
Catholic Health Initiatives' CTR is an emerging participant and partner in the realization of personalized medicine. The CTR, based in Towson, MD., is a national laboratory that leverages its molecular diagnostics, CLIA laboratory, biospecimen repository, and custom development capabilities to enable improved treatment options
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved